Intas Pharma bags another overseas co
Mint Ahmedabad|January 08, 2025
Gujarat-based drug-maker Intas Pharmaceuticals Ltd, which counts private equity firm ChrysCapital, Singapore state investment firm Temasek and Abu Dhabi Investment Authority (ADIA) as its investors, has signed a deal to acquire a biologic medication brand from US-based Coherus Biosciences.
Sreeja Biswas

Intas Pharma has agreed to buy Udenyca brand through its US specialty division, Accord BioPharma, for up to $558.4 million (nearly ₹4,800 crore), according to a press release.

Udenyca is the brand name for medication pegfilgrastim-cbqv, a bone marrow stimulant used to treat low white blood-cell counts in patients who take cancer medications.

This story is from the January 08, 2025 edition of Mint Ahmedabad.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.

This story is from the January 08, 2025 edition of Mint Ahmedabad.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.

MORE STORIES FROM MINT AHMEDABADView All
Mint Ahmedabad

The Treasures of Nimrud Pieced Together Again

The UNESCO-listed archaeological site was ravaged by Islamic State fighters

time-read
2 mins  |
January 09, 2025
Mint Ahmedabad

From arrack to wine, a bar crawl across Sri Lanka

Cocktail bars in the island nation are drawing on local traditions and flavours to give a heady twist to familiar spirits

time-read
3 mins  |
January 09, 2025
Mint Ahmedabad

The Asian Dream is waking up to realities of middle-class life

Asians are realizing that staying middle-class is not guaranteed

time-read
3 mins  |
January 09, 2025
Mint Ahmedabad

Only human-centred AI can charm humans to adopt it

The AI industry could learn from carmakers how to focus on the consumer and modify perceptions

time-read
3 mins  |
January 09, 2025
Mint Ahmedabad

How Emerging Economies Could Prosper in a Protectionist World

As manufacturing export success gets harder, they should focus on service exports. These are unlikely to face big trade barriers

time-read
4 mins  |
January 09, 2025
Mint Ahmedabad

Fix India's bond market to lift economic growth

As India's economy slows, we should revive public-private partnerships to attract private investment. But, for debt funding, we'll need to reform and invigorate our market for bonds

time-read
2 mins  |
January 09, 2025
Mint Ahmedabad

Lessons from the 75-year-old National Sample Survey

Its impressive history tells us much about innovation, autonomy and state-level data collection

time-read
3 mins  |
January 09, 2025
Mint Ahmedabad

We should let clarity prevail over nonsense: Here's a handy guide

We must use simple language, empathize with people, not take ourselves too seriously and be kind

time-read
4 mins  |
January 09, 2025
Mint Ahmedabad

Clear Goals and Discipline: How Small Investors Can Build Lasting Wealth

There is no one-size-fits-all, the answer will depend on your needs, personal preferences

time-read
3 mins  |
January 09, 2025
Mint Ahmedabad

How do I ensure my daughters get assets only at 25?

I am 50, a Hindu widower with two (5 and 7 years old) daughters.

time-read
2 mins  |
January 09, 2025